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The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP), a consortium of 10 prospective
cohort studies from the United States, Finland, and China, was formed to examine the associations between
circulating 25-hydroxyvitamin D (25(OH)D) concentrations and the risk of rarer cancers. Cases (total n ¼ 5,491)
included incident primary endometrial (n ¼ 830), kidney (n ¼ 775), ovarian (n ¼ 516), pancreatic (n ¼ 952), and
upper gastrointestinal tract (n ¼ 1,065) cancers and non-Hodgkin lymphoma (n ¼ 1,353) diagnosed in the partici-
pating cohorts. At least 1 control was matched to each case on age, date of blood collection (1974–2006), sex, and
race/ethnicity (n ¼ 6,714). Covariate data were obtained from each cohort in a standardized manner. The majority
of the serum or plasma samples were assayed in a central laboratory using a direct, competitive chemilumines-
cence immunoassay on the DiaSorin LIAISON platform (DiaSorin, Inc., Stillwater, Minnesota). Masked quality
control samples included serum standards from the US National Institute of Standards and Technology. Condi-
tional logistic regression analyses were conducted using clinically deﬁned cutpoints, with 50–<75 nmol/L as the
reference category. Meta-analyses were also conducted using inverse-variance weights in random-effects models.
This consortium approach permits estimation of the association between 25(OH)D and several rarer cancers with
high accuracy and precision across a wide range of 25(OH)D concentrations.
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Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention Study II Nutrition
Cohort; IARC, International Agency for Research on Cancer; NCI, National Cancer Institute; NIST, National Institute of Standards
and Technology; NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
Vitamin D has a central role in bone health, and deﬁcient
levels are associated with an increased risk of fractures and
musculoskeletal symptoms (1–3). Its possible role in other
disease outcomes such as cancer is less certain. Most studies
of cancer risk and vitamin D status have focused on cancers
at the more common sites, such as colorectal, breast, and
prostate cancer, but with the possible exception of colorectal
cancer (4), the evidence of an association is inconsistent (4–
7). Few studies of less common cancers have been con-
ducted, but of those that have, including investigations of
10 Am J Epidemiol 2010;172:10–20pancreatic and esophageal cancer, researchers have found
both inverse and elevated risks associated with vitamin D
(8–10). The possible broad role of vitamin D in overall
health, coupled with the high prevalence of vitamin D in-
sufﬁciencyand deﬁciency in the general population (11, 12),
has led to calls for increased vitamin D supplementation and
controversial recommendations to increase sun exposure in
order to raisevitamin D levels (13). However, because of the
potential for harm noted in at least 1 study of a rare but
highly lethal cancer (9), additional information concerning
the association of vitamin D with rarer cancers is needed.
Clues to the potential role of vitamin D in the develop-
ment of rarer cancers have come primarily from ecologic
studies which observed lower rates of ovarian cancer (11,
14–17), endometrial cancer (18), and non-Hodgkin lym-
phoma (5), among other cancers, in areas with high sunlight
exposure (the main source of vitamin D) as compared with
regions with lower sunlight exposure. However, ecologic
studies have well-known limitations, including inadequate
control for confounding variables and a lack of consider-
ation of other sources of vitamin D exposure. Case-control
studies also present challenges, such as the need for rapid
case ascertainment, especially for highly lethal cancers, and
the identiﬁcation of a sufﬁcient number of cases to ade-
quately address the proposed research question. Another
challenge that cannot be overcome using the traditional ret-
rospective case-control design is the impact of the disease
on the exposure, especially one such as vitamin D, where
both dietary intake and sun exposure may change as a result
of the illness.
Prospective etiologic studies can overcome the limita-
tions of both ecologic and case-control studies through the
measurement of vitamin D biomarkers (the best of which is
25-hydroxyvitamin D (25(OH)D) (19)) in blood samples
collected years before cancer diagnosis. However, few co-
horts contain adequate numbers of any particular rarer can-
cer, and the collection of serum vitamin D data in a single
cohort at a limited geographic location may result in a lack
of variability in vitamin D exposure. Collecting and analyz-
ing data from multiple cohort studies conducted at a wide
range of latitudes would increase both the number of cases
and the variation in 25(OH)D concentrations, improving the
ability to elucidate the true association between vitamin D
and the development of a rarer cancer.
In May 2007, a conference sponsored by the US National
Institutes of Health entitled ‘‘Vitamin D and Cancer: Cur-
rent Dilemmas/Future Needs’’ was held to critically evalu-
ate the scientiﬁc evidence related to vitamin D and cancer
risk, identify gaps in knowledge, and determine the type of
research needed to make science-based recommendations
regarding vitamin D intake/exposure for cancer prevention.
In response to a conference recommendation to conduct
prospective studies using stored biologic samples, a consor-
tium of prospective cohort studies was formed—the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers
(VDPP)—to study the association between circulating
25(OH)D concentrations and the development of the follow-
ing rarer cancers: endometrial, esophageal/gastric, kidney,
lymphoma, ovarian, and pancreatic. In this paper, we de-
scribe the design and methods of the VDPP.
MATERIALS AND METHODS
Overview of the National Cancer Institute VDPP
National Cancer Institute Cohort Consortium and cohorts
participating in the VDPP. The Cohort Consortium was
formed in 2000 under the direction of the National Cancer
Institute (NCI) to address the need for large-scale collabo-
rations for the study of genomic associations with cancer
(20, 21). The current study is the ﬁrst project of the Cohort
Consortium to examine a serologic factor and address mul-
tiple rarer cancer sites. The VDPP includes cohort studies
based in China, Finland, and the United States, including 1
with a study center in Hawaii. A common standard nested
case-control design was followed, and the vast majority
of blood samples for this study (collected between 1974
and 2006) were assayed at a single laboratory, permitting
rigorous investigation of the vitamin D hypothesis. The
cohorts included in the VDPP, their characteristics, and
their contributions to the VDPP data set are described in
Table 1 and Table 2. By choice, not all of the participating
cohort investigators contributed data on all of the cancer
types under study in the VDPP; there was no speciﬁc num-
ber of cases that a study’s investigators were required to
contribute, either overall or for a particular cancer type, to
participate.
Organizational structure and governance. The VDPP
Steering Committee was formed to oversee the design and
execution of the VDPP. The Steering Committee consisted
of the committee chair, investigators representing each of
the participating cohorts, the head of the Data Coordinating
Center, the lead laboratory investigator, and leaders of the
working groups. Personnel from the NCI’s Division of Can-
cer Control and Population Sciences and the NCI’s Division
of Cancer Epidemiology and Genetics also participated as
ex-ofﬁcio Steering Committee members. During the course
of the study, the Steering Committee met 3 times in person
at the annual NCI Cohort Consortium Conference in 2007,
2008, and 2009 and held monthly telephone conference
calls. Decisions were generally made by consensus, but
when voting was conducted, only representatives of the par-
ticipating cohorts were designated voting members, with 1
vote each.
Working groups. Working groups were established to di-
rect data analyses and write manuscripts for each cancer site
and an analysis of correlates of 25(OH)D concentrations.
Esophageal and gastric cancers were combined into 1 work-
ing group (upper gastrointestinal tract cancers); other cancer
sites each had a working group. Working group leaders were
chosen on a volunteer basis. The groups consisted of repre-
sentatives from each cohort study, except when the cohort
investigators were not providing serum samples or data for
the speciﬁc cancer site. The leader of each working group
was represented at the Steering Committee meetings. In
addition, statistical and quality control working groups were
created to develop the general statistical analysis plan and
quality control procedures. Working groups communicated
on a regular basis by e-mail or conference call.
Data Coordinating Center. All data for the VDPP were
maintained at the Data Coordinating Center led by the
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Cohort Study
(Reference No.(s)) Population Geographic Location
Size of Cohort With Blood
Specimens Dates of
Blood Draw
Type of Specimen
Collected
Case
Ascertainment
Date of Last
Follow-up
No. % Female
ATBC (22, 23) Smokers Finland 29,133 0 1985–1988 Serum Finnish Cancer Registry April 2005
a
CPS-II (24) General United States—national 39,380 56 1998–2001 Serum Cancer registry/medical
records/NDI
December 2004
CLUE I/CLUE II (25) General United States—Washington
County, Maryland
CLUE I: 3,165 59 CLUE I: 1974 Serum/
plasma
State and county
cancer registries
December 2007
CLUE II: 24,646 58 CLUE II: 1989
HPFS (26) Health
professionals
United States—national 18,225 0 1993–1995 Plasma Medical records/NDI 2006
MEC (27) General United States—Hawaii
and California
67,594 54 2001–2006 Serum SEER Registry December 2006
NYU-WHS (28) Mammography
screenees
United States—New York,
New York
14,274 100 1985–1991 Serum Questionnaire/New
Jersey, New York,
and Florida cancer
registries/NDI
July 2003
NHS (29–31) Registered nurses United States—national 32,826 100 1989–1990 Plasma Medical records/NDI 2004
PLCO (32, 33) General United States—national 66,000 50 1993–2001 Serum Questionnaire/medical
records
October 2005
SMHS (34) General Shanghai, China 16,119 0 2001–2006 Plasma Cancer registry August 2008
SWHS (35) General Shanghai, China 56,831 100 1997–2000 Plasma Cancer registry October 2008
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention Study II Nutrition Cohort; HPFS, Health Professionals Follow-up Study; MEC,
Multiethnic Cohort Study; NDI, National Death Index; NHS, Nurses’ Health Study; NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial; SEER, Surveillance, Epidemiology, and End Results; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
a April 2004 for pancreatic cancer and non-Hodgkin lymphoma.
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0Nutritional Epidemiology Branch of the NCI’s Division of
Cancer Epidemiology and Genetics. Information Manage-
ment Services, Inc. (Silver Spring, Maryland) served as the
data collection, database creation/storage, editing, and ana-
lytical unit. A secure portal for uploading of data from in-
dividual cohorts and the laboratory was established by
Westat, Inc. (Rockville, Maryland), with restricted access.
Approvals needed. Investigators in each cohort study
requested and received institutional review board approval
from their home institution(s) to participate in the VDPP. In
addition, the investigators for each cohort signed a data
transfer agreement with the NCI governing the approved
use of the data.
Study design and methods
Case and control deﬁnitions. Cases included all persons
with incident primary endometrial, kidney, ovarian, pancre-
atic, or upper gastrointestinal tract cancer or lymphoma who
had plasma or serum samples available (Table 3). Histologic
conﬁrmation was not required for inclusion of a case in the
VDPP; however, approximately 95% of the included cases
were histologically conﬁrmed (endometrial, 98.4%; kidney,
93.3%; lymphoma, 98.1%; ovarian, 96.3%; pancreatic,
82.0%; and upper gastrointestinal, 98.4%). In general, a sin-
gle control was matched to each case on age at blood col-
lection (61 year), sex, race/ethnicity (white/black/Asian/
other), and date of blood collection (630 days if possible).
Because, in some cases, cohort investigators may have pre-
viously selected case-control sets for prior studies, cases and
controls may have been matched on additional criteria, such
as fasting status or menopausal status at the time of blood
draw; inaddition, the matching criteria for the VDPP match-
ing variables may have differed (e.g., the matching criterion
for age at blood collection may have been 62 years instead
of 61 year). In particular, cases and controls in the New
York University Women’s Health Study (NYU-WHS) were
matched on the date of blood collection by 690 days. In
some instances, more than 1 control was matched to each
case.
To be eligible, controls had to be alive and free of cancer
(except possibly nonmelanoma skin cancer or cervical can-
cer in situ) and to possess the organ under study (e.g., uterus,
ovary), if this information was available, on the calendar
date on which their matched case’s cancer was diagnosed.
In total, 5,743 cases and 6,807 controls were initially iden-
tiﬁed for inclusion in the VDPP. After exclusions, which are
described in each site-speciﬁc manuscript, data from a total
of 5,491 cases and 6,714 matched controls were analyzed
(Table 3). The lymphoma working group restricted their
analyses to non-Hodgkin lymphoma, excluding other types
of lymphoma.
Vitamin D assays. Serum/plasma requirements. All
samples selected speciﬁcally for 25(OH)D measurement as
part of the VDPP were assayed at Heartland Assays, Inc.
(Ames, Iowa). For each case and control, 125 lL of either
serum or plasma was sent clot-free in a bar-coded screw-cap
microcentrifuge tube (Sarstedt AG & Company, Nu ¨mbrecht,
Germany). Published data indicate thattherewas noimpact of
type of specimen (serum or plasma) on 25(OH)D results
Table 2. Characteristics of Participants in the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers,
1974–2006
Cohort No. of
Cases
a
No. of
Controls
a
Race/Ethnicity Among VDPP
Controls, % Median Age (IQR
b)o f
VDPP Controls, years
Median Follow-up
Time (IQR) for VDPP
Cases, years White Black Asian Other
ATBC 1,223 1,747 100 0 0 0 58 (54–62) 8.7 (4.9–12.7)
CPS-II 376 382 98 <1 <1 1 70 (67–74) 2.3 (1.3–3.6)
CLUE 843 859 99 1 0 0 55 (47–64) 10.1 (5.3–14.7)
HPFS
c 133 147 94 0 1 2 67 (59–72) 4.4 (2.6–6.7)
MEC 408 413 13 24 26 37
d 70 (63–75) 2.1 (1.1–3.3)
NYU-WHS 441 469 72 11 <1 4 55 (48–60) 10.8 (6.0–14.6)
NHS 435 851 99 <1 <1 <1 57 (52–63) 7.0 (4.0–9.5)
PLCO 950 1,141 92 4 4 <1 65 (61–68) 4.5 (2.2–6.8)
SMHS 198 202 0 0 100 0 66 (55–70) 1.7 (0.9–2.7)
SWHS 484 503 0 0 100 0 59 (49–65) 4.7 (2.4–6.6)
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention
Study II Nutrition Cohort; IQR, interquartile range; MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study;
NYU-WHS, New York University Women’s Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study; VDPP, Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers.
a Includes cases and controls for certain cancer sites from the ATBC, NHS, and PLCO cohorts with previously
measured 25-hydroxyvitamin D levels; numbers reﬂect those cases and controls included in the site-speciﬁc anal-
yses (after exclusions described in the site-speciﬁc manuscripts).
b 25th–75th percentiles.
c For the HPFS, 3% of cohort participants were missing information on race/ethnicity.
d Includes Hispanics not categorized as being of ‘‘white’’ or ‘‘black’’ race/ethnicity.
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Am J Epidemiol 2010;172:10–20(36, 37) and that there was no decline in 25(OH)D concentra-
tions during 4 years of storage (38). Further, it has been shown
that 25(OH)D results obtained for specimens that are thawed
and refrozen up to 4 times are reliable (39), and therefore there
was no restriction based on previous thaw/freeze cycles for the
blood specimens. Measurement of 25(OH)D was conducted
by means of a direct, competitive chemiluminescence immu-
noassay using the DiaSorinLIAISON 25(OH)D TOTAL assay
(DiaSorin, Inc., Stillwater, Minnesota) (40). The assay is co-
speciﬁc for 25-hydroxyvitamin D3and25-hydroxyvitamin D2.
The assay utilizes a speciﬁc antibody to 25(OH)D for coating
magnetic particles (solid phase) and a vitamin D analog,
22-carboxy-23,24,25,26,27-pentanorvitamin D3,l i n k e dt oa n
isoluminol derivative. During the incubation, 25(OH)D is dis-
sociated from its binding protein and competes with the
isoluminol-labeled analog for binding sites on the antibody.
After the incubation, the unbound material is removed with
a wash cycle. Subsequently, the starter reagents are added and
a ﬂash chemiluminescent reaction is initiated. The light signal
is measured by a photomultiplier as relative light units and
is inversely proportional to the concentration of 25(OH)D
present in calibrators, controls, or samples.
Quality control. Several types of masked reference
samples were interspersed among study samples for assess-
ment of quality control. Investigators for each cohort were
provided with samples of the vitamin D standard (standard
reference material 972, Vitamin D in Human Serum) (41)
from the US National Institute of Standards and Technology
(NIST) at both level 1 (prepared from ‘‘normal’’ human
serum and not altered) (~60 nmol/L) and level 2 (prepared
by diluting level 1) (~35 nmol/L) to include with their sam-
ples. Every batch of 100 samples contained either 2 level-1
samples or 2 level-2 samples. In addition, masked quality
control samples were provided by the investigators from
each cohort, within each batch of their samples (either 2
or 4 cohort-speciﬁc quality control samples), in a manner
that resulted in overall quality control (including the NIST
samples) being 5% of the total sample. In general, the qual-
ity control samples provided by each cohort’s investigators
were either pooled samples from multiple subjects or spec-
imens from separate individuals that were repeated through-
out that cohort’s batches.
Coefﬁcients of variation for duplicate serum/plasma ali-
quots included in all laboratory sample batches were calcu-
lated for the 3 types of quality control samples: NIST level
1, NIST level 2, and each cohort quality control. The vari-
ance components model of SAS (PROC VARCOMP) was
used to estimate the variance between batches and within
batches and to calculate interbatch and intrabatch coefﬁ-
cients of variation (SAS Institute Inc., Cary, North Caro-
lina). Inter- and intrabatch coefﬁcients of variation for
NIST level-1 samples were 12.7% and 9.3%, respectively;
inter- and intrabatch coefﬁcients of variation for NIST level-
2 samples were 13.6% and 11.0%, respectively. The median
interbatch coefﬁcient of variation for the cohort quality con-
trol samples was 13.2% (range, 4.8%–17.0%); the median
intrabatch coefﬁcient of variation for the cohort quality con-
trol samples was 9.9% (range, 3.8%–16.4%).
Covariate information. A core set of covariates was se-
lected by the Steering Committee to be considered in the
statistical analyses of vitamin D and all of the rarer cancer
sites. These covariates were selected on the basis of pre-
viously published data on their associations with vitamin
D concentration and/or cancer in general and included de-
mographic characteristics, family history of cancer, anthro-
pometric factors, physical activity, alcohol use, supplement
use, medication use, smoking habits, hormone therapy, oral
contraceptive use, reproductive factors, sun exposure, his-
tory of certain diseases, and death data. Additional data on
dietary intake (especially sources of vitamin D and dairy
Table 3. Numbers of Cancer Cases Contributed By Each Cohort Participating in the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers, by Cancer Type, 1974–2006
a
Cancer Site ATBC CPS-II CLUE HPFS MEC NHS NYU-WHS PLCO SMHS SWHS Total
Endometrial 0 51 192 0 39 163 139 147 0 99 830
Kidney 286 58 102 0 64 0 35 161 32 37 775
Lymphoma
b 208 135 236 133 96 145 73 286 8 33 1,353
Ovarian 0 27 102 0 18 127 94 74 0 74 516
Pancreatic 313 65 123 0 109 0 73 183 27 59 952
Upper gastrointestinal
tract (esophagus and
stomach)
416 40 88 0 82 0 27 99 131 182 1,065
Total 1,223 376 843 133 408 435 441 950 198 484 5,491
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention
StudyIINutritionCohort;HPFS,HealthProfessionalsFollow-upStudy;MEC,MultiethnicCohortStudy;NHS,Nurses’
Health Study; NYU-WHS, New York University Women’s Health Study; PLCO, Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
a Totals include samples that were assayed for 25-hydroxyvitamin D levels prior to initiation of the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers (189 ATBC lymphoma cases, 200 ATBC pancreatic cancer
cases, 127 NHS ovarian cancer cases, and 183 PLCO pancreatic cancer cases and matched controls).
b Lymphoma cases that were not cases of non-Hodgkin lymphoma were excluded prior to analysis and therefore
are notincludedin thenumberspresentedin thetable. Thenumbersrepresent onlycasesof non-Hodgkin lymphoma.
14 Gallicchio et al.
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analysis on correlates of circulating 25(OH)D concentra-
tion. Each working group was then asked to submit a limited
‘‘wish list’’ of additional variables for which data would be
requested from the cohort studies’ investigators to be used in
that working group’s analysis.
After the complete list of variables was compiled from
the working groups, cohort investigators were asked to pro-
vide information about the availability of data on the vari-
ables and the time point of data collection (e.g., at the time
of blood draw; prior to or after blood draw). For most vari-
ables, information collected at the time of blood draw or
closest to the time of blood draw was used. A requested
variable was removed from the core data request list if data
were available from fewer than 4 cohorts. Working groups
were then asked to reexamine their list of desired variables
and revise it accordingly. For example, a working group
may have requested data on occupational history; these data
were available from only 3 of the cohorts and thus would
have had limited usefulness in the analyses.
The Steering Committee reviewed the ﬁnal variable list,
and the Data Coordinating Center sent a single, complete
data request form to investigators in each of the cohorts.
This request included the name of each speciﬁc variable,
the time point at which data for the variable were being
requested (either the date of blood draw or the index date
(date of the case’s diagnosis for both case and control(s)
in a matched set)), and the desired format for the variable.
The Data Coordinating Center cleaned and harmonized
the data on all variables. The decision was made not to
impute missing values; rather, missing values for each vari-
able were coded as a unique category so that cases and
controls were not dropped from the regression analyses
when data were missing.
Latitude is a variable of speciﬁc interest in investigations
of vitamin D. With the exception of the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study (ATBC), the Can-
cer Prevention Study Nutrition Cohort (CPS-II), the Pros-
tate, Lung, Colorectal and Ovarian Cancer Screening Trial
(PLCO), the Shanghai Men’s Health Study, and the
Shanghai Women’s Health Study, latitude was determined
using the ﬁrst 3 digits of the subject’s zip code. The ATBC
and Shanghai Men’s and Women’s Health Study subjects
were assigned the latitudes of 60 N (the latitude of Helsinki,
Finland) and 31 N (the latitude of Shanghai, China), respec-
tively. PLCO subjects were assigned latitudes on the basis
of the location of their local screening center. The CPS-II
investigators provided data on latitude. For stratiﬁed
analyses, latitude was categorized as <34 N, 34 N–42 N,
and >42 N. These cutpoints were based on data published
by Webb et al. (42) showing that at 42 N, cutaneous
production of vitamin D ceases from November through
February because of the angle of the sun and resulting de-
creases in the amount of ultraviolet B radiation that reaches
the earth’s surface and that at 34 N, vitamin D is synthe-
sized (although at low levels) all winter.
Statistical approaches. The strengths of the multisite co-
hort consortium approach also present challenges in terms
of the data analyses. A clear strength of the NCI Cohort
Consortium is the heterogeneity of regions and the diversity
ofpopulations. ThisCohortConsortiumstudyincludedaco-
hort from Finland, a population that has low vitamin D
exposure based on region, as well as cohorts comprised of
Asian and African-American populations, which also have
low vitaminD exposure because of skin pigmentation. Thus,
the highest percentile of circulating 25(OH)D concentra-
tions in these populations fell into the low-to-middle ranges
of concentrations in other populations. To avoid masking
any associations and to take advantage of the range of cir-
culating 25(OH)D concentrations, we used multiple analytic
approaches, including traditional pooling approaches and
meta-analysis modeling.
The decision was made to conduct the main analyses for
each cancer type using clinically deﬁned cutpoints (43–
45); the cutpoints used were <25, 25–<37.5, 37.5–<50,
50–<75, 75–<100, and  100 nmol/L. The referent cate-
gory chosen was 50–<75 nmol/L, because this concentra-
tion includes the mean concentration of the US population
(62.91 nmol/L (standard error, 0.81) for males and
61.54 nmol/L (standard error, 0.85) for females), based
on 2000–2004 National Health and Nutrition Examination
Survey data (46). Using these cutpoints, conditional logistic
regression analysis was used to examine the association
between 25(OH)D at high and low concentrations and the
development of cancer. For some analyses (e.g., stratiﬁed
analyses) for the individual cancer sites, the 2 highest cate-
gories were combined because ofinsufﬁcient numbers in the
highest category of circulating 25(OH)D. Tests for a trend in
the categorical 25(OH)D variable in these (and other) anal-
yses were performed using a Wald test, by assigning ordinal
scores (0, 1, 2, 3,...) to each of the 25(OH)D categories and
treating the variable as continuous in the regression model.
Concentrations of circulating 25(OH)D differ over the
course of the year with variations in sun exposure and sun
intensity. Cases and controls were matched within cohort
and as closely as possible by date of blood draw. Overall,
among controls measured for 25(OH)D as part of the VDPP,
83.5% were matched within 30 days of the exact date of
their matched case’s blood draw. Because matching within
30 days was not always possible, this requirement was re-
laxed for some matched pairs (5.9% of controls were
matched within 60 days of the case and 3.3% were matched
within 90 days of the case). Matching on month of blood
draw, without regard to year, was also allowed, if needed.
This was done for 110 controls, with the most extreme
difference in the exact date of blood draw being 6.3 years.
However, it is the month of the year that is most important
for vitamin D assays, and 85.7% of cases and controls were
matched within 30 days (regardless of year). In addition to
matching, several other approaches were used in the analy-
ses to deal with season: stratiﬁcation of models by season,
residual adjustment for season, and use of season-speciﬁc
cutpoints.
Based on the distributions of circulating 25(OH)D data
among controls, both overall and by cohort, 2-, 3-, and 4-
category season variables were deﬁned and tested. It was
determined that the 2-season deﬁnition of ‘‘summer’’ (June–
November) and ‘‘winter’’ (December–May) adequately
characterized the seasonality differences, based on similar
median circulating 25(OH)D concentrations by month,
Design and Methods of the VDPP 15
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category. Therefore, all of the analyses discussed in the
cancer-site-speciﬁc manuscripts were conducted using the
2-category season variable. Season-stratiﬁed analyses using
the 2-category seasonvariable were conducted for each can-
cer site using unconditional logistic regression, adjusting for
matching factors. The 4-category season variable was used
in the analysis of the correlates of 25(OH)D concentration,
as described in the paper by McCullough et al. (47). The
4-season variable was categorized as: winter, January–
March; spring, April–June; summer, July–September; and
fall, October–December.
Use of regression residuals to adjust for season takes into
account the gradual nature of changes in concentrations of
25(OH)D over the year, which may be better than adjusting
for season. For residual adjustment for season, the residuals
of circulating 25(OH)D concentrations (log-transformed)
against week of blood draw were calculated using the local
polynomial regression method (48). This adjustment was
based on data from controls for all tumor sites within sex-
and cohort-speciﬁc groups (with previously assayed sam-
ples, such as those from the ATBC Study, done separately)
and then applied to all cases within those speciﬁc groups.
The residual data were cut into sex- and cohort-speciﬁc
quartiles based on the control distribution, and then all re-
sidual data were merged together. Conditional logistic re-
gression analyses were conducted with the lowest quartile
designated the referent category.
For models with season-speciﬁc cutpoints, pooled analy-
ses were conducted using cohort-, sex-, and season-speciﬁc
quartile cutpoints (using the 2-seasonvariable), based on the
distribution of circulating 25(OH)D concentrations among
all control subjects from all cancer sites combined. This
allowed for greater stability and resulted in the use of the
same cutpoint deﬁnition across all cancer sites. A second set
of quartile categories was created that were not cohort-
speciﬁc, whereby cohorts with lower circulating 25(OH)D
values fell mainly into the lower quantiles. Results obtained
for each cancer site were similar for the ﬁrst (cohort-
speciﬁc) and second (not cohort-speciﬁc) sets of categories;
thus, only results for the cohort-speciﬁc cutpoints are pre-
sented in the site-speciﬁc manuscripts.
Finally, using the a priori clinically deﬁned cutpoints, a 2-
stage meta-analysis based on the methods described by
Smith-Warner et al. (49) was conducted. Results for each
cancer type are presented for high concentrations of
25(OH)D (deﬁned as either  100 nmol/L or  75 nmol/L,
depending on the number of cases for a speciﬁc cancer type)
versus the reference category (50–<75 nmol/L) and for low
concentrations of 25(OH)D (deﬁned as either <25 nmol/L
or <37.5 nmol/L) versus the reference category. Cohort-
speciﬁc odds ratios were estimated and then pooled using
inverse-variance weights in random-effects models. The
heterogeneity of cohort-speciﬁc estimates was measured us-
ing the DerSimonian and Laird Q statistic (50), and data are
presented as forest plots.
Stratiﬁed analyses. Stratiﬁed analyses were conducted
using conditional models for sex, race/ethnicity, and histo-
logic subtype and unconditional models, adjusting for the
matching factors, for variables such as season, age, and
body mass index. To examine latency effects, stratiﬁed anal-
yses were also conducted for each cancer site based on time
from blood draw to cancer diagnosis ( 5 years vs. >5 years
and  2 years vs. >2 years). In addition, each working group
conducted stratiﬁed/subgroup analyses based on factors rel-
evant to the speciﬁc tumor site.
Interaction tests were conducted for continuous variables
by crossing the median values of each of the 25(OH)D cat-
egories with the median value (based on controls) of the
stratiﬁed variable. The resulting continuous values were
added to the model, and the P value for the interaction term
was calculated. For categorical variables, multiple interac-
tion terms were created, one for each level of the categorical
variable crossed with the continuous variable, and the log-
likelihood test was used to compare models with and with-
out the interaction terms.
Confounding. The process used for identiﬁcation of
confounding factors was determined by the working group
for each individual cancer site. Therefore, confounder iden-
tiﬁcation is described in the Materials and Methods section
of each site-speciﬁc manuscript.
Inclusion of previous data. For this study, 9,855 sam-
ples were assayed for 25(OH)D centrally for the VDPP and
included in the site-speciﬁc analyses. In addition, investiga-
tors from some participating cohort studies contributed data
from previously assayed samples (ATBC—non-Hodgkin
lymphoma: 189 cases/506 controls; pancreatic cancer: 200
cases/400 controls; PLCO—pancreatic cancer: 183 cases/
364 controls; Nurses’ Health Study—ovarian cancer:
127 cases/381 controls). The distribution of circulating
25(OH)D concentrations among controls in the previously
assayed samples was compared with the distribution of
vitamin D concentrations from controls of the same cohort
assayed as part of the VDPP; these samples were found to
differ by an average of 31%, but the differences were not
systematic when examined by cohort, race/ethnicity, age,
and season. Therefore, no adjustments or calibration of
the vitamin D data were performed, and the raw data from
previously assayed samples were added to the categories of
clinically deﬁned cutpoints. Note that the calculation of co-
hort-, sex-, and season-speciﬁc quartiles, described above,
was conducted separately for the previous data. Sensitivity
analyses were conducted in these site-speciﬁc analyses after
excluding these previously analyzed cases and controls; data
from previously assayed samples were not included in the
correlates analysis.
VITAMIN D DATA
Table 4 shows meanvalues, medianvalues, and interquar-
tile ranges for circulating 25(OH)D concentrations mea-
sured as part of the VDPP (and not including the previous
data) among controls, overall and by cohort. Among the
controls of the participating cohorts, the Health Profes-
sionals Follow-up Study had the highest mean circulating
25(OH)D concentrations, and CPS-II had the highest me-
dian circulating 25(OH)D concentrations. The ATBC Study
had the lowest mean and median circulating 25(OH)D con-
centrations. None of the circulating 25(OH)D measurements
from samples collected within the Shanghai Women’s
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median 25(OH)D concentrations among controls in the
VDPP were 50.6 nmol/L and 48.1 nmol/L, respectively.
The distribution of 25(OH)D concentrations among the con-
trols was right-skewed.
SUMMARY AND CHALLENGES
The potential role of vitamin D in health should be well
understood so the public can be informed of both the ben-
eﬁts and potential risks of increasing vitamin D concentra-
tions through supplementation or sun exposure. Recently,
a working group of the International Agency for Research
on Cancer (IARC) published a monograph calling for more
extensive clinical trials to evaluate the health effects of vi-
tamin D supplementation prior to instituting supplementa-
tion recommendations (5). Randomized clinical trials are
critical, but such trials are expensive, focus on a speciﬁc
dose, examine effects that occur late in disease progression,
deal by nature with selected populations, and are not prac-
tical for examining rare outcomes with long latency periods
such as the rarer cancers examined here. Well-conducted
observational studies, though discounted in value by the
IARC report, are complementary to clinical trials and in
many cases will provide the only obtainable evidence of
beneﬁt or harm associated with speciﬁc exposures. Long-
term prospective studies of circulating vitamin D concen-
trations can examine a range of exposure levels, can assess
long-term health outcomes in populations closer in terms of
characteristics to the general population than those included
in clinical trials, and may cost-effectively examine the as-
sociation between dose and multiple rarer outcomes. The
VDPP provides a unique contribution to understanding the
association between vitamin D concentrations resulting
from a wide range of vitamin D exposures and subsequent
development of rarer cancers, overcoming many of the lim-
itations of ecologic and case-control studies. Thus, this type
of study provides complementary data to those which may
be obtained from randomized clinical chemoprevention
trials.
One of the principal strengths of the VDPP is the number
of cases of rarer cancers included; these case numbers, be-
cause of the contribution of 10 cohorts, exceed those of
other, single-site observational studies and allow for rigor-
ous analysis of the associations examined. Further, the co-
horts in the VDPP have a wide geographic distribution,
covering extremes in latitude and thus sun exposure. This
variation in latitude and sun exposure permits the estimation
of cancer risks at very high and low vitamin D concentra-
tions, in contrast to single-site observational studies, which
may have a limited range of vitamin D values. Other
strengths of the VDPP were the availability of prospectively
collected blood samples for measurement of 25(OH)D as an
integrated biomarker of vitamin D exposure (instead of ex-
amining vitamin D using dietary information and/or sun
exposure data only); the use of a centralized laboratory to
perform the vitamin D assays, which allowed for the stan-
dardization of vitamin D assay methods and instrument cal-
ibration; and the availability of the NIST standards for
quality control.
Despite the strengths of the VDPP, therewere a number of
inherent challenges to the project that arose primarily from
the same source as its strengths. Unlike clinical trials, in
which common data elements are determined and collected
speciﬁcally for the study, this project included existing
cohorts that had diverse methods of data collection. Thus,
data collection and harmonization of data elements were
challenging, and some variables that may have been
Table 4. Circulating 25-Hydroxyvitamin D Concentrations (nmol/L) Measured Among Controls
in the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, Overall and By Cohort,
1974–2006
a
Cohort Mean (SD) Minimum 25th Percentile Median 75th Percentile Maximum
ATBC 35.8 (20.5) 2.4 20.3 31.8 48.4 145.6
CPS-II 61.6 (23.0) 16.6 46.0 59.7 74.4 143.0
CLUE 61.2 (25.0) 5.7 44.3 58.8 74.7 189.9
HPFS 61.8 (22.4) 10.0 45.8 58.6 76.6 138.7
MEC 53.1 (24.6) 5.0 35.3 50.2 66.6 146.3
NYU-WHS 48.7 (22.0) 6.4 32.8 46.4 62.1 140.9
NHS 56.8 (22.6) 9.9 41.1 53.8 69.4 145.4
PLCO 55.1 (21.6) 10.2 40.3 53.6 66.7 188.8
SMHS 40.9 (17.7) 9.2 28.2 38.0 50.3 106.8
SWHS 36.6 (15.7) 2.9 25.0 33.4 44.5 98.7
Total 50.6 (24.0) 2.4 33.1 48.1 64.4 189.9
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II,
Cancer Prevention Study II Nutrition Cohort; HPFS, Health Professionals Follow-up Study;
MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study; NYU-WHS, New York University
Women’s Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial;
SD, standarddeviation;SMHS,ShanghaiMen’sHealthStudy;SWHS,ShanghaiWomen’sHealth
Study.
a Previously assayed samples were not included.
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of missing data was also a challenge, and ultimately a de-
cision was made to not impute data. Further, despite the
large sample size overall for each cancer site in comparison
with previous studies, the numbers were small when the
analyses were stratiﬁed on certain variables.
An often-cited limitation of serologic studies is the reli-
ance on a single 25(OH)D measurement per subject. Sub-
stantial variation in 25(OH)D concentrations over time has
been shown in a number of published studies (5, 43), and
25(OH)D status at a single time point may not accurately
reﬂect a person’s long-term 25(OH)D exposure. However,
the NYU-WHS investigators conducted a pilot study to as-
sess the temporal reliability of 25(OH)D values using 3 sam-
ples collected at yearly intervals from 30 healthy NYU-WHS
participants (15 premenopausal and 15 postmenopausal) and
found that temporal reliability, estimated using the intraclass
correlation coefﬁcient, was excellent (intraclass correlation
coefﬁcient ¼ 0.78, 95% conﬁdence interval: 0.64, 0.88)
(A. Zeleniuch-Jacquotte, New York University School
of Medicine, personal communication, 2009). Similarly,
an analysis using data obtained in the Nurses’ Health
Study showed an intraclass correlation coefﬁcient of 0.72
(95% conﬁdence interval: 0.62, 0.80) for 25(OH)D concen-
trations measured in 71 women over a period of 2–3 years
(S. E. Hankinson, Harvard School of Public Health, personal
communication, 2009). This result is comparable to that ob-
served in 144 middle-aged men, for whom the correlation
between samples collected 3 years apart was 0.70 (51).
Seasonal variation in vitamin D concentrations is another
potential limitation to serologic studies and is probably
more important at higher latitudes than at lower latitudes
because of the wide variations in sun elevation angles with
increasing latitude (5). The long-term intraindividual varia-
tion of circulating 25(OH)D concentrations across seasons
has not been well studied and thus is not well understood.
Nakamura et al. (52) reported a Pearson correlation coefﬁ-
cient of 0.46 (P < 0.0001) for correlation between circulat-
ing concentrations of 25-hydroxyvitamin D3, a major
component of 25(OH)D, measured in the summer and the
fall among 122 healthy Japanese women aged 41–81 years.
In this study, to minimize bias from seasonal variation,
a number of strategies were employed in both the design
of the study and the analytic methods, including matching
on the date of blood draw, using season-speciﬁc cutpoints to
create exposure categories, stratifying on season, and con-
ducting residual-adjusted analyses. In general, the results
from these analyses were consistent for all cancer sites;
however, the possibility of bias due to inaccurate classiﬁca-
tion of long-term 25(OH)D exposure cannot be ruled out.
Despite the claim by the IARC vitamin D working group
that ‘‘new observational studies are unlikely to disentangle
the complex relationships between vitamin D and known
cancer risk factors’’ (5, p. 1), consortial approaches such
as the VDPP are complementary to clinical trials, address-
ing aspects that may only be answered by long-term obser-
vational studies, particularly for determining associations
with rare cancer outcomes. Study designs are complemen-
tary, since no one study and no one type of study design are
likelyto be sufﬁcient to answer these types of questions. The
VDPP represents one step towards understanding the rela-
tion between vitamin D and the development of rarer
cancers.
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